| GlaxoSmithKline AG - AREXVY, Pulver und Suspension zur Herstellung einer Injektionssuspension | | 69310 | | 01 | | AREXVY | | Pulver und Suspension zur Herstellung einer Injektionssuspension | | J07BX05 | | | | 02.05.2024 | | |
| | Composition | | I): proteinum prae-fusionatum F viri sincitialis respiratorii 120 µg, trehalosum dihydricum, polysorbatum 80, kalii dihydrogenophosphas, dikalii phosphas anhydricus, pro vitro.
II): Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml.
I) et II) corresp.: proteinum prae-fusionatum F viri sincitialis respiratorii 120 µg, trehalosum dihydricum, polysorbatum 80, kalii dihydrogenophosphas, dikalii phosphas anhydricus, Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, natrii chloridum, dinatrii phosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.78 mg, kalium 0.35 mg. | | Packungsbestandteile | | | | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | PR | PR | B | | No |
|
|
